⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL22492378 | 0.79 | ALDH1A1 (0.36) | — | |
| SCHEMBL14087042 | 0.76 | NLRP3 (0.40) | — | |
| SCHEMBL22492426 | 0.75 | — | — | |
| Methane SCHEMBL22492564 | 0.72 | — | — | |
| Methane SCHEMBL22492568 | 0.72 | USP2 (0.32) | — | |
| SCHEMBL26247536 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL27744190 | 0.72 | — | — | |
| Methane SCHEMBL22492468 | 0.72 | ALDH1A1 (0.33) | — | |
| SCHEMBL28700132 | 0.71 | KMT2A (0.33) | — | |
| SCHEMBL905490 | 0.71 | TSHR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111417620-A | Creatine prodrugs, compositions thereof, and methods of use | 奥特吉尼克斯制药公司 | 2020-07-14 | — | — | CN | disclosed |